Management of Locally Advanced Non-small Cell Lung Cancer by 議곗옱�샇
J Lung Cancer 2009;8(1):1-7
1
Management of Locally Advanced Non-small Cell Lung 
Cancer
Locally advanced Non-small cell lung cancer (NSCLC) is a commonly 
encountered diagnosis. Historically the treatment of locally advanced NSCLC 
has involved radiation therapy. Clinical trials have shown a benefit to the 
addition of chemotherapy. In recent years studies have further defined the 
role of chemotherapy by provided data showing the benefit of concurrent 
chemotherapy and radiation therapy followed by consolidation with more 
chemotherapy. Technological advances in radiation therapy have made dose 
escalation feasible and the current treatment paradigm is now evolving further 
as dose escalation data becomes available. (J Lung Cancer 2009;8(1):1󰠏7)
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INTRODUCTION
  Lung cancer is the leading cause of cancer related deaths 
worldwide (1). It is estimated that 215,000 new cases will be 
diagnosed for 2009 in the United States alone. Approximately 
80% of diagnosed lung cancers are non-small cell lung cancer 
(NSCLC). Upon initial presentation, less than one-half of 
patients will have surgically resectable lung cancer with the 
potential for surgical cure. Approximately one-third of patients 
will present with locally advanced disease involving either the 
ipsilateral mediastinal/subcarinal lymph nodes (American Joint 
Committee on Cancer [AJCC] Tl-3 N2 MO, Stage IIIA) or any 
contralateral mediastinal, hilar or ipsilateral or contralateral 
scalene or supraclavicular nodes (AJCC Tl-2 N3 MO, Stage 
IIIB) without evidence of extrathoracic metastases. A smaller 
number of patients will have a centrally located primary tumor 
involving mediastinal structures (AJCC T4 Nx MO, Stage 
IIIB). Traditionally, these patients are generally not considered 
candidates for surgical resection, and have been treated with 
other therapeutic modalities.
  Prior to the 1990’s, patients with locally advanced NSCLC 
were treated with radiation therapy alone. Unfortunately, the 
radiation therapy technique and dose used produced dismal 
survival rates of 40%, 15% and 5% at 1, 2 and 5 years 
respectively. Since that time, several advances have occurred in 
the treatment of locally advanced NSCLC. A number of phase 
III clinical trials have established the importance of combining 
chemotherapy with radiation therapy in the treatment of locally 
advanced NSCLC. Clinical trials have also provided data that 
demonstrates surgery is unlikely to offer improvement in 
outcome over other modalities for this group of patients. 
Concurrent chemoradiation is now widely accepted as standard 
of care. Recently technological advances in radiation therapy 
have shown promise in further improving the outcome for 
patients with locally advanced NSCLC. These advances have 
shown that it may be possible to increase delivered radiation 
dose. Preliminary data suggest that these techniques may 
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improve survival with acceptable levels of toxicity.
The Evolution of Combined Modality Therapy
  During the 1990’s a shift occurred in the treatment of locally 
advanced NSCLC from radiotherapy alone to concurrent 
chemoradiation. A number of randomized phase II/III trials 
each played a role in the evolution of therapy to the current 
standard of concurrent chemoradiation. The process began with 
the development of sequential chemotherapy followed by 
radiation therapy.
Sequential Chemotherapy
  A series of clinical trials investigating the use of sequential 
chemotherapy and radiation therapy were performed in the mid 
to late 1980’s. The rationale of these trials was based on the 
premise that full doses of chemotherapy and radiation therapy 
could successfully be administered sequentially. They hypo-
thesized that the chemotherapy would act to eliminate un-
detectable systemic micrometastatic disease while radiation 
therapy would act as a potent local treatment.
  The Cancer and Leukemia Group B (CALGB) 8433 trial, 
also sometimes referred to as the Dillman trial, is notable for 
being an early trial that established the importance of the 
addition of chemotherapy in locally advanced NSCLC. The trial 
enrolled 155 patients with clinical stage III NSCLC. Patients 
were randomized to receive induction chemotherapy with 
cisplatin/vinblastine or no induction chemotherapy (2,3). All 
patients were also treated with conventionally fractionated 
radiation therapy to a total dose of 60 Gy. Analysis of the study 
showed a statistically significant improvement in the median 
survival of 13.7 months over 9.6 months (p=0.012) with se-
quential chemoradiation over radiation alone. The 5 year sur-
vival rate tripled with combined modality therapy over radiation 
alone (17% vs. 6%). It is also important to note that the sequen-
tial treatment regimen was not associated with an increase in 
clinically significant toxicity.
  The CEBI 138 trial by Le Chevalier et al. (also known as 
IGR or French trial) randomized 353 patients to one of two 
arms. Those in the first arm received a conventionally frac-
tionated course of thoracic radiotherapy to a total dose of 65 
Gy. Patients in the other arm received induction and consoli-
dation chemotherapy. The chemotherapy arm schedule con-
sisted of 3 monthly cycles of induction chemotherapy con-
sisting of vindesine, cyclophosphamide, cisplatin, and lomustine 
(VCPC), followed by a course of thoracic radiotherapy, then 
followed by 3 additional monthly cycles of VCPC (4,5). The 
results of this trial were similar to those of the Dillman trial 
with a statistically significant benefit in 3 year survival rate 
with sequential chemoradiation over radiation alone (12% vs. 
4%). One interesting result was that there appeared to be a 50% 
relative risk reduction of distant metastases in the chemotherapy 
arm, supporting the hypothesis that chemotherapy could reduce 
micrometastatic disease.
  The benefit of sequential chemotherapy was further con-
firmed by an intergroup trial (RTOG 88-08, ECOG 4588, 
S8892) performed by Radiation Therapy Oncology Group 
(RTOG), Eastern Cooperative Oncology Group (ECOG), and 
Southwest Oncology Group (SWOG) reported by Sause and 
colleagues (6,7). The design of this trial was somewhat 
different from the prior trials mentioned because it had a three 
arm randomization. The trial enrolled 452 patients with 
unresectable NSCLC (although it should be noted that it 
included a small number of stage II patients) to one of two 
radiation alone arms (daily to 60 Gy or twice-daily to 69.6 Gy) 
or to the third arm of induction with cisplatin and vinblastine 
followed by a daily radiotherapy to 60 Gy, in the same manner 
as the CALGB 8433 trial. The trial was designed to test if the 
results of the CALGB trial could be confirmed and also to test 
the possible benefit of hyperfractionated radiation therapy. Of 
the three arms, the sequential chemotherapy and radiation arm 
had superior results with a statistically significant improvement 
in overall and median survival, thus adding further confirmation 
to the benefit offered by the addition of chemotherapy.
  These randomized trials established the importance of the 
addition of chemotherapy in the treatment of locally advanced 
NSCLC. The addition of induction chemotherapy reduced 
distant relapse and improved survival (Table 1). However, after 
the completion of these trials, questions still remained regarding 
the optimal timing of chemotherapy in combination with 
radiation therapy.
Concurrent Chemotherapy and Radiation Therapy
  Despite the therapeutic improvement that was observed with 
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Table 1. Multicenter Phase III Randomized Controlled Trials Comparing Sequential Chemoradiation vs. Radiation Alone
Study Sequence Pts
RT 
dose
(Gy)
CT
Local-regional
control Median
survival
(months)
Overall survival
Acute≥grade 
3 toxicity (%)3 yr 
(%)
5 yr 
(%)
3 yr 
(%)
5 yr 
(%)
CALGB 8433 (2,3)
RTOG 8808 (6,7) 
CEBI 138 (4,5) 
qdRT
CT→qdRT
qdRT
CT→RT
bidRT
qdRT
CT→qdRT
 77
 78
152
152
154
167
165
 60
 60
 60
 60
 69.9
 65
 65
N/A
cddp/vinblastine
N/A
cddp/vinblastine
N/A
N/A
VCPC
 6
18
n.r.
n.r.
n.r.
17 (1 yr)
15 (1 yr)
 5
 6
n.r.
n.r.
n.r.
n.r.
n.r.
  9.6
 13.7
 11.4
 13.8
 12.3
10
12
 6
24
11
17
14
 4
12
 6
17
 5
 8
 6
 3
 6
7
3
1
1
3
3
5
RT: radiotherapy, CT: chemotherapy, n.r.: not reported, qd: daily, bid: twice daily, cddp: cisplatin, VCPC: vindesine, cyclo-
phosphamide, cisplatin, and lomustine, Pts: number of patients
the addition of induction chemotherapy, the prognosis of locally 
advanced NSCLC remained relatively poor. This was due to 
both continued problems with distant recurrence and also poor 
local control. In an effort to improve local control, trials were 
performed to evaluate the possible benefit of concurrent 
chemotherapy and radiation. The hypothesis of these trials was 
that the chemotherapy would act as a radiosensitizer. The 
possible mechanisms of chemotherapeutic radiosensitization are 
thought to be direct inhibition of repair of radiation-induced 
damage, elimination of radioresistant, chemosensitive clones, 
and/or suppression of inter-fraction tumor repopulation (8-10). 
The following phase III randomized trials have shown a 
statistically significant improvement in clinical outcomes 
including survival with the concurrent approach.
  The first key trial to evaluate concurrent chemoradiation was 
the West Japan Lung Cancer Group (WJLCG) trial. This study 
enrolled 314 patients with locally advanced NSCLC who were 
randomized to receive either concurrent or sequential chemo-
radiation therapy (11). The chemotherapy used in the study was 
mitomycin, vindesine, and cisplatin (MVP). A split course of 
56 Gy of radiation therapy was used in the concurrent arm 
while 56 Gy was given continuously in the sequential arm. The 
trial revealed a statistically significant improvement in median 
survival (16.5 vs. 13.3 months), 5-year survival (15.8% vs. 
8.9%), and response rate (84% vs. 66%). Interestingly, the trial 
seemed to support the hypothesis that local control could be 
improved by concurrent therapy. In the concurrent arm 
local-failure free survival was significantly greater (30 vs. 11 
months) while the rate of distant failure was similar between 
both arms. This result was achieved in the context of split 
course radiation therapy, which is now widely considered to be 
an inferior approach. The only significance in toxicity between 
the two arms was an increase in myelosuppression in the 
concurrent arm.
  The RTOG 9410 was a phase III randomized trial of 610 
patients with unresectable stages II/III NSCLC (8,9). The trial 
was designed to investigate both a possible benefit of concur-
rent therapy and hyperfractionation. Patients were randomized 
to three arms: sequential chemotherapy and daily radiation, 
concurrent chemotherapy and daily radiation, or twice-daily 
radiation treatments. There was a statistically significant impro-
vement in median survival (17.0 vs. 14.6 months; p=0.0038) 
and 4 year survival rate (21% vs. 12%; p=0.046) in the con-
current daily arm over the sequential arm. It was also sig-
nificantly better than the twice-daily treatment arm. Acute 
toxicity rated grade 3 or higher was increased in the concurrent 
daily arm over that of the sequential arm (55% vs. 35%).
  Another significant study was performed in the Czech Re-
public by Zatloukal et al. The trial included 102 patients who 
were randomized to cisplatin/vinorelbine given either as in-
duction to or concurrent with 60 Gy (10). The study revealed 
that concurrent therapy resulted in significant improvement in 
median survival (16.6 vs. 12.9 months) and time to progression 
(11.9 vs. 8.5 months). There was also a significant improve-
ment in overall response rate of 80% vs. 47% with the con-
current approach. Consistent with other studies, there was 
increased toxicity associated with the concurrent arm. Speci-
fically, there were increases in leukopenia (53% vs. 19%), nau-
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Table 2. Multicenter Phase III Randomized Controlled Trials Comparing Concurrent with Sequential Chemoradiotherapy
Study Sequence Pts
RT dose 
(Gy)
CT
Locoregional
control Median
survival
(months)
Overall 
survival Acute ≥ 
grade 3
esophagitis (%)3 yr
(%)
5 yr
(%)
3 yr 
(%)
5 yr 
(%)
West Japan lung 
 cancer 
Group (WJLCG) (11) 
RTOG 9410 (8,9)
Czech republic 
 study (10)
CT→qdRT
CT+qdRT
CT→qdRT
CT+qdRT
CT+bidRT
CT→qdRT
CT+qdRT
 158
 156
 201
 201
 193
  50
  52
56
56 (split 
course)
60
60
69.6
60
60
MVP
MVP
cddp/vinblastine
cddp/vinblastine
cddp/etoposide
cddp/vinorelbine
cddp/vinorelbine
n.r.
n.r.
n.r.
n.r.
n.r.
40%
58%
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
n.r.
 13.3
 16.5
 14.6
 17
 15.1
 12.9
 16.6
 15
 22
 n.r.
 n.r.
 n.r.
  9.5
 18.6
 9
16
10
16
13
n.r.
n.r.
 2
 3
 4
23
46
 4
18
RT: radiotherapy, CT: chemotherapy, qd: daily, bid: twice daily, MVP: mitomycin, vindesine, and cisplatin, cddp: cisplatin, n.r.: not 
reported, Pts: number of patients
sea/vomiting (39% vs. 15%), and esophagitis (17.6% vs. 4.2%). 
  The results of these studies provide compelling evidence that 
an approach using concurrent chemoradiation results in superior 
clinical outcome when compared to sequential therapy (Table 
2). This improvement is associated with an increase in local 
control thought to result from radiosensitization. However, it is 
important to note that this improvement in local control comes 
at the cost of increased toxicity. Each of these randomized trials 
consistently demonstrated that more acute toxicity occurs when 
concurrent therapy is administered. These trials established 
concurrent chemoradiation as standard of care, but with time 
the role of chemotherapy has been further defined.
Concurrent Chemoradiation with 
Induction or Consolidation
  Sequential chemoradiation improved clinical outcomes by 
providing better systemic control, while concurrent chemoradi-
ation seems to improve locoregional control. A logical hy-
pothesis is that combining both of these approaches could 
improve efficacy through better local and systemic control. 
Indeed, this hypothesis led phase II/III trials designed to 
combine concurrent chemoradiation with either induction or 
consolidation chemotherapy.
  SWOG S9019 was a phase II trial that confirmed the 
feasibility of full-dose chemotherapy consisting of cisplatin and 
etoposide given concurrent with and after 61 Gy radiotherapy 
(12). Fifty patients were enrolled with pathologically confirmed 
stage IIIB NSCLC. The study resulted in a median survival of 
15 months and 3-year survival of 17%. The results were 
encouraging enough that a follow-up study, S9504, was 
conducted. S9504 included 83 patients stage IIIB NSCLC who 
were treated with concurrent chemoradiation followed by 
consolidative chemotherapy (13,14). In a recent update, median 
follow-up was 71 months with a median progression free 
survival (PFS) of 16 months, median survival time (MST) of 
26 months, and 5-year survival of 29%. The results of these 
SWOG studies indicated that consolidation chemotherapy was 
feasible and may be of additional benefic to concurrent che-
moradiation. 
  The American College of Radiology (ACR) 427 trial, also 
known as LAMP (Locally Advanced Multimodality Protocol), 
was a phase II trial that randomized 256 patients with 
unresected stage III NSCLC to one of three arms to determine 
the optimal sequencing of carboplatin/paclitaxel chemotherapy 
and daily radiation to 63 Gy (15). Randomization arms were 
as follows: (A) chemotherapy followed by radiotherapy alone 
(sequential), (B) chemotherapy followed by concurrent che-
moradiation (induction/concurrent), and (C) concurrent che-
moradiation followed by chemotherapy (concurrent/consoli-
dation). Unfortunately, the trial was open during a period when 
the superiority of concurrent therapy was being established and 
the sequential arm closed early with poor accrual as a result. 
However, the trial is significant because it compares induction 
chemotherapy to consolidation chemotherapy in the setting of 
concurrent chemoradiation. At a median follow-up of 39.6 
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months, the median overall survival was 13.0, 12.7, and 16.3 
months, respectively, favoring the concurrent/consolidation arm. 
It is important to note that there was increased toxicity in the 
concurrent/consolidation arm. Despite this, the authors con-
cluded that the concurrent/consolidation arm had superior cli-
nical outcomes.
  Though there is no phase III data addressing the question of 
consolidation chemotherapy, the SWOG 9504 (13,14) and 
LAMP (15) trials suggest a benefit of consolidation chemo-
therapy in the setting of concomitant chemoradiation and this 
is a common clinical practice.
Surgery for Stage IIIA
  The development of concurrent chemoradiation with con-
solidation chemotherapy has improved outcomes for patients 
with locally advanced lung cancer. Despite this, the outcome 
for these patients is still unacceptably poor. One of the 
proposed ways of continuing to improve the outcome of these 
patients, specifically those with stage IIIA disease, is the 
addition of surgery to improve local control. In the late 1990’s 
two important trials were designed and opened to address this 
question.
  The first trial to directly test the role of surgery in stage IIIA 
disease was the North American Intergroup trial 0139 (RTOG 
9309). This study enrolled 396 patients with stage IIIA 
NSCLC, good performance status and technically resectable 
disease (16). Patients initially received chemotherapy with ci-
splatin and etoposide along with concurrent thoracic radio-
therapy to 45 Gy. Patients were then randomized to receive 
either additional radiotherapy to a total of 61 Gy or to have 
surgical resection. The updated results of the trial do show a 
small improvement in median progression free survival for the 
arm that included surgery (12.9 vs. 10.5 months, p=0.017), but 
this failed to result in an increase in overall survival. Another 
important result to note from this trial was the high rate of 
operative mortality for patients requiring a pneumonectomy for 
surgical resection.
  The EORTC also organized a trial to investigate the role of 
surgery in stage IIIA NSCLC (EORTC 08941). The study 
included 579 patients with stage IIIA-N2 NSCLC who were 
treated with platinum based chemotherapy. Of these patients, 
332 (57%) had at least a minimal response and were 
randomized (17). Patients then went on to have surgical resec-
tion or received chemoradiation to a total dose of at least 60 
Gy. Patients in the surgery arm were eligible for post-operative 
radiation therapy if there were positive surgical margins. This 
resulted in 39% of patients going on to receive post-operative 
radiation therapy. Interestingly, there was no difference in either 
progression free survival or overall survival between the two 
arms. Consistent with the results of the Intergroup 0139 trial, 
patients who were treated by pneumonectomy had especially 
poor outcomes with high post-operative mortality.
  The results of the Intergroup 0139 and EORTC 08941 
unfortunately fail to demonstrate any significant benefit to 
surgical resection for patients with stage IIIA NSCLC. Due to 
this demonstrated lack of benefit, concurrent chemoradiation 
and consolidation chemotherapy largely remain the treatment 
program of choice for patients with locally advanced NSCLC. 
Attempts to improve the treatment of locally advanced NSCLC 
are now focused on enhancing radiation therapy and chemo-
therapy.
Radiation Dose
  Approximately 35 years ago the RTOG conducted a trial 
which established 60 Gy as the optimal standard radiation dose 
for locally advanced NSCLC (RTOG 73-01) (18). Based on this 
trial, doses from 55∼66 Gy are still used today as 
demonstrated by the doses used in the studies already discussed 
in this review. It is important that the dose of 60 Gy was 
established as optimal before the advent of modern imaging and 
3-D radiation therapy techniques. These more modern 
techniques include CT-based treatment planning, conformal 
radiation therapy, positron emission tomography (PET), and 
knowledge of tumor motion during radiation delivery. Another 
major shift in treatment strategy was the irradiation of gross 
disease without prophylactic/elective nodal irradiation. There 
were several reasons for this philosophy. The dose of radiation 
commonly employed (60 Gy/30 fractions) was not enough to 
sterilize bulky epithelial tumors. Simply increasing the dose 
delivered to the large volumes of the chest included when 
irradiating lymph nodes prophylactically was believed to cause 
unacceptable toxicity. Additionally, irradiating clinically unin-
volved nodal areas prophylactically did not appear rational 
when the gross tumor was infrequently controlled. The impro-
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vement in technology and change in treatment volumes have 
made it feasible to attempt dose escalation in the treatment of 
locally advanced NSCLC. Due to the sub-optimal local control 
that is achieved with the current standard of concurrent che-
moradiation, there has been inquiry into the hypothesis that 
increased radiation dose will improve local control.
  A number of groups have performed radiation dose 
escalation trials for locally advanced NSCLC and reported 
encouraging results. The following studies demonstrate the 
feasibility and potential efficacy of increased radiation dose.
  RTOG 0117 trial is a phase I/II radiation dose escalation 
protocol (19). The treatment protocol also includes concurrent 
chemotherapy. The phase I portion enrolled 17 patients and 
began at a dose level of 75.25 Gy in 2.15 Gy daily fractions 
along with weekly carboplatin and paclitaxel. Three of the eight 
patients treated to 75.25 Gy developed dose-limiting pulmonary 
toxicity leading to a dose de-escalation to 74 Gy in 2 Gy daily 
fractions. Nine additional patients accrued and the maximum 
tolerated dose was determined to be 74 Gy. There is data 
available on 24 patients from the phase II portion and thus far 
the median survival is 21.6 months (median follow-up for all 
patients: 8.9 months; median follow-up for live patients: 7.3 
months).
  The NCCTG conducted a phase I trial of a radiation dose 
escalation with concurrent chemotherapy. Results were pre-
sented at ASTRO 2005 (NCCTG 0028). Carboplatin, pacli-
taxel and 3-D radiotherapy with no elective nodal radiation 
were used to treat 13 patients (20). Similar to the findings of 
RTOG 0117, the MTD of N0028 was determined to be 74 Gy. 
With a median follow-up of 28 months, the median survival 
time was 37 months.
  The University of North Carolina investigators reported a 
phase I/II study that escalated radiation dose to 74 Gy from 
a starting dose of 60 Gy (21,22). Chemotherapy consisted of 
induction carboplatin and paclitaxel and, in contrast to other 
studies it was administered as induction for two cycles followed 
by concurrent chemoradiation with the same agents. Modern 
3-D planning was used to escalate to the following doses: 60 
Gy, 66 Gy, 70 Gy, and 74 Gy. With a median follow-up of 
43 months, the median survival was 24 months. The overall 
survival rate was 50% at two years and 38% at three years. 
Based on this study, 74 Gy was judged to be safe in the setting 
of concurrent chemotherapy consistent with other trials.
  The currently accepted standard of care for patients with 
inoperable stage III NSCLC is concurrent chemoradiation the-
rapy, but there is still a need to improve clinical outcome. The 
accepted standard radiation dose is 63∼66 Gy, but phase I/II 
trials have demonstrated a maximum tolerated dose of 74 Gy 
(RTOG, NCCTG, and North Carolina) with encouraging 
median survivals. The RTOG is conducting a phase III trial to 
test two hypotheses. First, higher radiation doses lead to better 
survival for patients with unresectable stage II-III non-small- 
cell lung cancer (NSCLC). Second, in addition to overall sur-
vival, median survival, disease-free survival, and local/regional 
tumor control will be assessed. The study RTOG 0617 also 
includes a 2×2 design which will also test the possible benefit 
of an antibody to the epidermal growth factor receptor (EGFR), 
cetuximab.
  Advances in the treatment of locally advanced lung cancer 
have led to the current standard of concurrent chemoradiation 
with consolidation chemotherapy. Continued advances in tech-
nology now make is possible to escalate radiation doses even 
higher. The addition of new chemotherapeutic or targeted 
agents may also further enhance therapy. The results of the 
current phase III dose escalation trial offer the promise of 
exciting advancement in the treatment of locally advanced 
NSCLC.
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